{"slug":"what-are-peptides-ibd","verification":{"valid":true,"entries":2,"head":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"},"energy":{"passes":2,"tokens_in":17466,"tokens_out":3021,"tokens_total":20487,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"},"provenance":[{"ts":"2026-06-29T21:57:50.870Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Ibd\nSlug: what-are-peptides-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-ibd\",\"title\":\"What Are Peptides for IBD\",\"body\":\"## What's breaking down\\n\\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\\n\\n## Why BPC-157 might help you\\n\\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\\n\\n## How these fit together\\n\\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\\n\\n## What the evidence actually shows\\n\\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document","tokens_in":17466,"tokens_out":3021,"cost":0,"prev":"genesis","hash":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7"},{"ts":"2026-07-17T02:43:32.414Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-ibd","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7","hash":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"}]}